Lenvatinib is FDA approved for the treatment of radioactive iodine-refractory differentiated thyroid cancer (DTC), unresectable or advanced hepatocellular carcinoma (HCC), and advanced renal cell carcinoma (RCC). It is a multiple receptor tyrosine kinase inhibitor that demonstrates potent antiangiogenic properties.
Product Name | Lenva |
Generic Name | Lenvatinib Mesylate |
Therapeutic Class | TKI |
Formulation | Solid |
Available Pack Size | 2x8's, 2x6's |
Available Strength | 4 mg, 10 mg |